Home Knowledge Base Zepbound

Zepbound

No mentions found

This entity hasn't been tracked yet, or Iris is still building its knowledge base.

Related Articles from SNS

Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy.

There is a new wave of weight-loss therapies in development that aim to be better than the existing GLP-1s.

MarketWatch 3d ago

Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk

Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk Popular GLP-1 weight-loss drugs may have an unexpected bonus: a significantly lower risk of breast cancer. - Date: - June 6, 2026 - Source: - University of Pennsylvania School of Medicine - Summary: - A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop breast cancer.

Science Daily 3d ago

Noom Promo Codes: 50% Off Best Deals & Free Trials for June 2026

Founded in 2008, Noom was launched as a human-to-human weight loss coaching service, which paired psychology-based methods with fitness and food tracking to help its users reach their weight goals. Since the rise of GLP-1 medications, Noom has also introduced a model that helps GLP-1 users taking WeGovy, Ozempic, Zepbound, or similar medications create sustainable lifestyle changes and healthy habits. It has also introduced the option for AI coaching.

Wired 1d ago

The next goal for weight loss drugs? Fewer injections

For millions of people taking weight loss drugs, the next breakthrough may not be more weight loss. It may be fewer injections. Pfizer and Amgen are developing monthly GLP-1 shots — a departure from injections like Wegovy and Zepbound, which are taken weekly.

NBC News 3d ago

Jim Cramer says he can't sell Eli Lilly despite its massive run up. Here's why

Eli Lilly 's expanding obesity drug pipeline is giving us little reason to take profits at this point — even after a massive run to record highs. "It's a parabolic spike. I don't buy parabolas," Jim Cramer said on " Squawk on the Street " on Monday.

CNBC 1d ago

Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage

Novo Nordisk and Eli Lilly took their GLP-1 pill battle to the preeminent obesity meeting this weekend as they prepare for the next sea change in how patients receive their drugs. Novo Nordisk on Sunday announced that prescriptions of the Wegovy pill have topped 3 million since it entered the U.S. market about five months ago. The Danish drugmaker's CEO Mike Doustdar celebrated the milestone, saying in an interview with CNBC that Novo was able to accelerate prescriptions even as Lilly...

CNBC 1d ago

GLP-1 drugs, including Ozempic, may have a beneficial effect across many types of cancer

GLP-1 drugs, including Ozempic, may have a beneficial effect across many types of cancer More than two dozen studies suggest the treatments are linked to lower cancer risk, reduced metastasis and improved survival, though researchers say trials are needed to confirm any anti-cancer benefit. A growing body of evidence suggests that popular GLP-1 drugs, widely used for weight loss and diabetes, can provide protection against many types of cancer. More than two dozen studies presented over the...

Channel News Asia 6d ago

Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas

Jacob Van Naarden is busy. In addition to running Eli Lilly's oncology business, he's now responsible for finding the drugmaker's next opportunities as head of business development. And Lilly, now the world's largest pharmaceutical company, is hungrier than ever for deals.

CNBC 7d ago

US adds popular Chinese firms to Pentagon's 'Chinese military company' list: Who's on it?

The Pentagon on Monday reinstated and expanded a list of Chinese companies it accuses of supporting China's military, naming major firms including Alibaba Group Holding, Baidu Inc., Tencent Holdings and electric vehicle maker BYD Co. The move is likely to add further strain to already tense US-China relations. The US Department of Defense said the companies had been added to its so-called 1260H list, which identifies entities determined by Washington to be aiding China's People's Liberation...

Times of India 1d ago